Ionis Pharmaceuticals
Develops antisense medicines through owned launches and pharmaceutical partnerships.
$61.05
After-hours close+0.01 (+0.02%)
At close$61.04(−2.23%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 117.66%Insiders 0.76%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 166.18M · Float 162.93M · 98.0% free float
Institutions13F, as of Jun 30, 2026
554 holders · 195.54M shares · 71 new positions · 278 increased · 152 reduced · 46 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 24.63M | 14.82% | +75.3K | Aug 13, 2026 |
| Capital World Investors | 21.67M | 13.04% | +482.9K | Aug 12, 2026 |
| BlackRock, Inc. | 10.70M | 6.44% | +262.2K | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 7.86M | 4.73% | +50.6K | Aug 13, 2026 |
| Wellington Management Group LLP | 7.65M | 4.60% | +1.26M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 7.21M | 4.34% | +93.2K | Aug 13, 2026 |
| Two Sigma Investments, LP | 6.25M | 3.76% | +394.7K | Aug 14, 2026 |
| Royal Bank of Canada | 6.18M | 3.72% | +2.38M | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Capital World Investors | 12.80% | 21.19M | 13G | May 14, 2026 ↗ |
| Wellington Group Holdings LLPincl. Wellington Management Company LLP, Wellington Investment Advisors Holdings LLP +1 more | 5.76% | 9.07M | 13G | Nov 8, 2024 ↗ |
| BlackRock, Inc. | 5.70% | 9.07M | 13G | Apr 17, 2025 ↗ |
| Vanguard Capital Management | 5.05% | 8.34M | 13G | Apr 30, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Brett P. Monia | director, officer: Chief Executive Officer | 245.6K | 0.15% | Jun 26, 2026 |
| Spencer R. Berthelsen | director | 161.2K | 0.10% | Jul 17, 2026 |
| Elizabeth L. Hougen | officer: EVP, Finance & CFO | 82.7K | 0.05% | Mar 18, 2026 |
| Michael R. Hayden | director | 78.3K | 0.05% | Jul 31, 2026 |
| Eugene Schneider | officer: EVP, Chf Clinical Develop Ofcr | 77.1K | 0.05% | Jun 30, 2026 |
| C. Frank Bennett | officer: EVP, Chief Scientific Officer | 75.0K | 0.05% | Jul 9, 2026 |
| Brian Birchler | officer: EVP, Corp and Development Ops | 67.5K | 0.04% | Apr 17, 2026 |
| Patrick R. O'Neil | officer: EVP CLO & General Counsel | 61.5K | 0.04% | Jun 30, 2026 |
| Richard S. Geary | officer: EVP, Chief Development Officer | 59.7K | 0.04% | Nov 7, 2025 |
| Joseph H. Wender | director | 52.0K | 0.03% | Dec 3, 2025 |
7 people have not refiled in the last 18 months (139.7K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 30, 2026 | Michael R. Haydendirector | Purchase | 15,000 | $53.38 | 19,000 |
| Jul 31, 2026 | Michael R. Haydendirector | Purchase | 5,000 | $51.60 | 24,000 |
| Jul 7, 2026 | Holly B. Kordasiewiczofficer: EVP, Chief Development Officer | Sale | 362 | $84.30 | 22,096 |
| Jul 7, 2026 | Allene M. Diazdirector | Sale | 10,111 | $85.42 | 3,811 |
| Jul 7, 2026 | C. Frank Bennettofficer: EVP, Chief Scientific Officer | Sale · 2 lots | 20,536 | $84.95 | 75,018 |
| Jul 1, 2026 | Joseph Iii Kleindirector | Sale · 2 lots | 11,518 | $79.04 | 11,014 |
| Jun 26, 2026 | Eugene Schneiderofficer: EVP, Chf Clinical Develop Ofcr | Sale | 26,000 | $81.05 | 77,114 |
| Jun 26, 2026 | Patrick R. O'Neilofficer: EVP CLO & General Counsel | Sale | 3,069 | $80.00 | 61,470 |
| Jun 26, 2026 | Joseph Baroldiofficer: EVP, Chief Business Officer | Sale | 5,635 | $80.16 | 4,669 |
| Jun 25, 2026 | Eric Swayzeofficer: EVP Research | Sale | 10,602 | $79.18 | 21,759 |
CongressHouse and Senate disclosures
Not reported.